A citation-based method for searching scientific literature

J Mazieres, C Cropet, L Montané, F Barlesi, P J Souquet, X Quantin, C Dubos-Arvis, J Otto, L Favier, V Avrillon, J Cadranel, D Moro-Sibilot, I Monnet, V Westeel, J Le Treut, E Brain, J Trédaniel, M Jaffro, S Collot, G R Ferretti, C Tiffon, C Mahier-Ait Oukhatar, J Y Blay. Ann Oncol 2020
Times Cited: 59







List of co-cited articles
658 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



A method and server for predicting damaging missense mutations.
Ivan A Adzhubei, Steffen Schmidt, Leonid Peshkin, Vasily E Ramensky, Anna Gerasimova, Peer Bork, Alexey S Kondrashov, Shamil R Sunyaev. Nat Methods 2010
1

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.
Diana Schaufler, David F Ast, Hannah L Tumbrink, Nima Abedpour, Lukas Maas, Ayla E Schwäbe, Inga Spille, Stefanie Lennartz, Jana Fassunke, Mihaela Aldea,[...]. NPJ Precis Oncol 2021
3
33

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.
Y S Li, B Y Jiang, J J Yang, X C Zhang, Z Zhang, J Y Ye, W Z Zhong, H Y Tu, H J Chen, Z Wang,[...]. Ann Oncol 2018
132
1

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
Yi-Chen Zhang, Zhi-Hong Chen, Xu-Chao Zhang, Chong-Rui Xu, Hong-Hong Yan, Zhi Xie, Shao-Kun Chuai, Jun-Yi Ye, Han Han-Zhang, Zhou Zhang,[...]. EBioMedicine 2019
22
4

Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients.
Panli Peng, Guoli Lv, Jinwei Hu, Kai Wang, Junhong Lv, Gang Guo. Ann Transl Med 2021
2
50


Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge.
Alejandro Ríos-Hoyo, Laura Moliner, Edurne Arriola. Cancers (Basel) 2022
2
50

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.
Alexa B Schrock, Viola W Zhu, Wen-Son Hsieh, Russell Madison, Benjamin Creelan, Jeffrey Silberberg, Dan Costin, Anjali Bharne, Ioana Bonta, Thangavijayan Bosemani,[...]. J Thorac Oncol 2018
80
1

Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.
Sun Min Lim, Nicholas L Syn, Byoung Chul Cho, Ross A Soo. Cancer Treat Rev 2018
135
1

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review.
Yijia Guo, Jun Song, Yanru Wang, Letian Huang, Li Sun, Jianzhu Zhao, Shuling Zhang, Wei Jing, Jietao Ma, Chengbo Han. Front Oncol 2020
22
4


The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis.
Hao Zhang, Zhengqiang Bao, Hongwei Liao, Wen Li, Zhihua Chen, Huahao Shen, Songmin Ying. Oncotarget 2017
8
12

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.
Shuhang Wang, Stella T Tsui, Christina Liu, Yongping Song, Delong Liu. J Hematol Oncol 2016
109
1


Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.
Ayesha Murtuza, Ajaz Bulbul, John Paul Shen, Parissa Keshavarzian, Brian D Woodward, Fernando J Lopez-Diaz, Scott M Lippman, Hatim Husain. Cancer Res 2019
99
1

Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Mingguang Zhang, Yunyun Wang, Jia Wang, Zhaogang Liu, Jingmiao Shi, Mingxin Li, Yongqiang Zhu, Shifa Wang. Chem Pharm Bull (Tokyo) 2020
6
16

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.
Yuichiro Ohe, Fumio Imamura, Naoyuki Nogami, Isamu Okamoto, Takayasu Kurata, Terufumi Kato, Shunichi Sugawara, Suresh S Ramalingam, Hirohiko Uchida, Rachel Hodge,[...]. Jpn J Clin Oncol 2019
64
1

Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand,[...]. N Engl J Med 2005
1

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
Masaaki Hibi, Hiroyasu Kaneda, Junko Tanizaki, Kazuko Sakai, Yosuke Togashi, Masato Terashima, Marco Antonio De Velasco, Yoshihiko Fujita, Eri Banno, Yu Nakamura,[...]. Cancer Sci 2016
25
4

ALK-rearrangement in non-small-cell lung cancer (NSCLC).
Xue Du, Yun Shao, Hai-Feng Qin, Yan-Hong Tai, Hong-Jun Gao. Thorac Cancer 2018
91
1


Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives.
Giulio Rossi, Genny Jocollé, Antonia Conti, Marcello Tiseo, Federica Zito Marino, Giovanni Donati, Renato Franco, Francesca Bono, Francesca Barbisan, Francesco Facchinetti. Lung Cancer (Auckl) 2017
34
2

A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients.
Preenumol Thomas, Bini Vincent, Christeena George, Julie Mariam Joshua, K Pavithran, Meenu Vijayan. Indian J Med Res 2019
6
16

Sotorasib: First Approval.
Hannah A Blair. Drugs 2021
35
2

The role of the ALK receptor in cancer biology.
B Hallberg, R H Palmer. Ann Oncol 2016
159
1

MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
Rebecca S Heist, Hyo Sup Shim, Shalini Gingipally, Mari Mino-Kenudson, Long Le, Justin F Gainor, Zongli Zheng, Martin Aryee, Junfeng Xia, Peilin Jia,[...]. Oncologist 2016
70
1

Hypoxia-induced angiogenesis: good and evil.
Bryan L Krock, Nicolas Skuli, M Celeste Simon. Genes Cancer 2011
614
1

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach.
Enric Carcereny, Alonso Fernández-Nistal, Araceli López, Carmen Montoto, Andrea Naves, Cristina Segú-Vergés, Mireia Coma, Guillem Jorba, Baldomero Oliva, Jose Manuel Mas. Oncotarget 2021
5
20


Mammography screening and mortality by risk status in the California teachers study.
Hannah Lui Park, Jenny Chang, Vikram Haridass, Sophia S Wang, Argyrios Ziogas, Hoda Anton-Culver. BMC Cancer 2021
1
100

Targeting mutant KRAS.
Daniel A Erlanson, Kevin R Webster. Curr Opin Chem Biol 2021
4
25


Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
Erin L Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao. Transl Lung Cancer Res 2015
201
1

Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
Yu Wang, Zheng Chen, Xiao Han, Jiamei Li, Honglin Guo, Junping Shi. Oncologist 2021
7
14

Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report.
Julie Mariam Joshua, Salima Kd, Pavithran K, Meenu Vijayan. Clin Med Insights Case Rep 2018
3
33

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
Suresh S Ramalingam, James C-H Yang, Chee Khoon Lee, Takayasu Kurata, Dong-Wan Kim, Thomas John, Naoyuki Nogami, Yuichiro Ohe, Helen Mann, Yuri Rukazenkov,[...]. J Clin Oncol 2018
309
1

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers.
Tingting Jiang, Guan Wang, Yao Liu, Lu Feng, Meng Wang, Jie Liu, Yi Chen, Liang Ouyang. Acta Pharm Sin B 2021
35
2

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
Nele Van Der Steen, Chiara Caparello, Christian Rolfo, Patrick Pauwels, Godefridus J Peters, Elisa Giovannetti. Onco Targets Ther 2016
25
4

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
51
1

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
Keunchil Park, Jin-Soo Kim, Joo-Hang Kim, Young-Chul Kim, Hoon-Gu Kim, Eun Kyung Cho, Jong-Youl Jin, Miyoung Kim, Angela Märten, Jin-Hyoung Kang. BMC Cancer 2021
3
33

MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer.
Ying Zhang, Lu Guo, Yuhuan Li, Gui-Hai Feng, Fei Teng, Wei Li, Qi Zhou. Mol Cancer 2018
187
1


Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.
Pranshu Bansal, Diaa Osman, Gregory N Gan, George R Simon, Yanis Boumber. Front Oncol 2016
24
4

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
David H Johnson, Louis Fehrenbacher, William F Novotny, Roy S Herbst, John J Nemunaitis, David M Jablons, Corey J Langer, Russell F DeVore, Jacques Gaudreault, Lisa A Damico,[...]. J Clin Oncol 2004
1

Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study.
Hind El Yacoubi, Mohamed Lemine Sow, Fouad Kettani, Lamia Gamra, Amina Mestari, Lamia Jabri, Ibrahim Elghissassi, Hassan Errihani. BMC Cancer 2020
4
25

The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study.
Keiko Tanimura, Tadaaki Yamada, Ayaka Omura, Shinsuke Shiotsu, Nobutaka Kataoka, Takayuki Takeda, Ryusuke Taniguchi, Takahiro Yamada, Mayumi Takeuchi, Yusuke Chihara,[...]. Front Oncol 2021
5
20

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.
Qiming Wang, Sen Yang, Kai Wang, Shi-Yong Sun. J Hematol Oncol 2019
99
1


Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
D Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R Hansen, Martin Hyrcza, Monika Krzyzanowska,[...]. Curr Oncol 2021
13
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.